OBGYN Evaluation - January 26, 2018

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1	The information and/or skills learned will enhance my professional competence or ability. - 0
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 0

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Describe the limitations of population-based screening.	Describe the limitations of population-based screening. - 5	Describe the limitations of population-based screening. - 4	Describe the limitations of population-based screening. - 3	Describe the limitations of population-based screening. - 2	Describe the limitations of population-based screening. - 1	Describe the limitations of population-based screening. - 0
Recognize the impact of improved breast cancer risk assessment and awareness of the spectrum of biologic behavior of breast cancers on screening and the approach to risk reduction.	Recognize the impact of improved breast cancer risk assessment and awareness of the spectrum of biologic behavior of breast cancers on screening and the approach to risk reduction. - 5	Recognize the impact of improved breast cancer risk assessment and awareness of the spectrum of biologic behavior of breast cancers on screening and the approach to risk reduction. - 4	Recognize the impact of improved breast cancer risk assessment and awareness of the spectrum of biologic behavior of breast cancers on screening and the approach to risk reduction. - 3	Recognize the impact of improved breast cancer risk assessment and awareness of the spectrum of biologic behavior of breast cancers on screening and the approach to risk reduction. - 2	Recognize the impact of improved breast cancer risk assessment and awareness of the spectrum of biologic behavior of breast cancers on screening and the approach to risk reduction. - 1	Recognize the impact of improved breast cancer risk assessment and awareness of the spectrum of biologic behavior of breast cancers on screening and the approach to risk reduction. - 0
Compare personalized screening to annual screening as described in an ongoing pragmatic trial.	Compare personalized screening to annual screening as described in an ongoing pragmatic trial. - 5	Compare personalized screening to annual screening as described in an ongoing pragmatic trial. - 4	Compare personalized screening to annual screening as described in an ongoing pragmatic trial. - 3	Compare personalized screening to annual screening as described in an ongoing pragmatic trial. - 2	Compare personalized screening to annual screening as described in an ongoing pragmatic trial. - 1	Compare personalized screening to annual screening as described in an ongoing pragmatic trial. - 0
Describe the characterization and pathophysiology of severe preeclampsia.	Describe the characterization and pathophysiology of severe preeclampsia. - 5	Describe the characterization and pathophysiology of severe preeclampsia. - 4	Describe the characterization and pathophysiology of severe preeclampsia. - 3	Describe the characterization and pathophysiology of severe preeclampsia. - 2	Describe the characterization and pathophysiology of severe preeclampsia. - 1	Describe the characterization and pathophysiology of severe preeclampsia. - 0
Effectively manage severe preeclampsia and reduce morbidities by utilizing evidence-based treatment approaches when patients present with severe preeclampsia.	Effectively manage severe preeclampsia and reduce morbidities by utilizing evidence-based treatment approaches when patients present with severe preeclampsia. - 5	Effectively manage severe preeclampsia and reduce morbidities by utilizing evidence-based treatment approaches when patients present with severe preeclampsia. - 4	Effectively manage severe preeclampsia and reduce morbidities by utilizing evidence-based treatment approaches when patients present with severe preeclampsia. - 3	Effectively manage severe preeclampsia and reduce morbidities by utilizing evidence-based treatment approaches when patients present with severe preeclampsia. - 2	Effectively manage severe preeclampsia and reduce morbidities by utilizing evidence-based treatment approaches when patients present with severe preeclampsia. - 1	Effectively manage severe preeclampsia and reduce morbidities by utilizing evidence-based treatment approaches when patients present with severe preeclampsia. - 0
Identify and weigh the risks and benefits of vaginal delivery versus Cesarean section.	Identify and weigh the risks and benefits of vaginal delivery versus Cesarean section. - 5	Identify and weigh the risks and benefits of vaginal delivery versus Cesarean section. - 4	Identify and weigh the risks and benefits of vaginal delivery versus Cesarean section. - 3	Identify and weigh the risks and benefits of vaginal delivery versus Cesarean section. - 2	Identify and weigh the risks and benefits of vaginal delivery versus Cesarean section. - 1	Identify and weigh the risks and benefits of vaginal delivery versus Cesarean section. - 0
Describe and implement key strategies to avoid the need for a Cesarean section.	Describe and implement key strategies to avoid the need for a Cesarean section. - 5	Describe and implement key strategies to avoid the need for a Cesarean section. - 4	Describe and implement key strategies to avoid the need for a Cesarean section. - 3	Describe and implement key strategies to avoid the need for a Cesarean section. - 2	Describe and implement key strategies to avoid the need for a Cesarean section. - 1	Describe and implement key strategies to avoid the need for a Cesarean section. - 0
Explain the role of accurate delivery data analysis in preventing Cesarean sections.	Explain the role of accurate delivery data analysis in preventing Cesarean sections. - 5	Explain the role of accurate delivery data analysis in preventing Cesarean sections. - 4	Explain the role of accurate delivery data analysis in preventing Cesarean sections. - 3	Explain the role of accurate delivery data analysis in preventing Cesarean sections. - 2	Explain the role of accurate delivery data analysis in preventing Cesarean sections. - 1	Explain the role of accurate delivery data analysis in preventing Cesarean sections. - 0
Recognize the role interventional radiology has played in the safe and effective treatment of postpartum hemorrhage.	Recognize the role interventional radiology has played in the safe and effective treatment of postpartum hemorrhage. - 5	Recognize the role interventional radiology has played in the safe and effective treatment of postpartum hemorrhage. - 4	Recognize the role interventional radiology has played in the safe and effective treatment of postpartum hemorrhage. - 3	Recognize the role interventional radiology has played in the safe and effective treatment of postpartum hemorrhage. - 2	Recognize the role interventional radiology has played in the safe and effective treatment of postpartum hemorrhage. - 1	Recognize the role interventional radiology has played in the safe and effective treatment of postpartum hemorrhage. - 0
Describe the indications for uterine artery embolization and its positive impact on patient outcomes.	Describe the indications for uterine artery embolization and its positive impact on patient outcomes. - 5	Describe the indications for uterine artery embolization and its positive impact on patient outcomes. - 4	Describe the indications for uterine artery embolization and its positive impact on patient outcomes. - 3	Describe the indications for uterine artery embolization and its positive impact on patient outcomes. - 2	Describe the indications for uterine artery embolization and its positive impact on patient outcomes. - 1	Describe the indications for uterine artery embolization and its positive impact on patient outcomes. - 0
Effectively diagnose and manage pelvic venous incompetence utilizing the latest concepts in interventional radiology.	Effectively diagnose and manage pelvic venous incompetence utilizing the latest concepts in interventional radiology. - 5	Effectively diagnose and manage pelvic venous incompetence utilizing the latest concepts in interventional radiology. - 4	Effectively diagnose and manage pelvic venous incompetence utilizing the latest concepts in interventional radiology. - 3	Effectively diagnose and manage pelvic venous incompetence utilizing the latest concepts in interventional radiology. - 2	Effectively diagnose and manage pelvic venous incompetence utilizing the latest concepts in interventional radiology. - 1	Effectively diagnose and manage pelvic venous incompetence utilizing the latest concepts in interventional radiology. - 0
Compare results from neoadjuvant breast cancer trials and their confirmatory phase 3 adjuvant trials.	Compare results from neoadjuvant breast cancer trials and their confirmatory phase 3 adjuvant trials. - 5	Compare results from neoadjuvant breast cancer trials and their confirmatory phase 3 adjuvant trials. - 4	Compare results from neoadjuvant breast cancer trials and their confirmatory phase 3 adjuvant trials. - 3	Compare results from neoadjuvant breast cancer trials and their confirmatory phase 3 adjuvant trials. - 2	Compare results from neoadjuvant breast cancer trials and their confirmatory phase 3 adjuvant trials. - 1	Compare results from neoadjuvant breast cancer trials and their confirmatory phase 3 adjuvant trials. - 0
Describe results from the I SPY 2 adaptive platform trial in breast cancer.	Describe results from the I SPY 2 adaptive platform trial in breast cancer. - 5	Describe results from the I SPY 2 adaptive platform trial in breast cancer. - 4	Describe results from the I SPY 2 adaptive platform trial in breast cancer. - 3	Describe results from the I SPY 2 adaptive platform trial in breast cancer. - 2	Describe results from the I SPY 2 adaptive platform trial in breast cancer. - 1	Describe results from the I SPY 2 adaptive platform trial in breast cancer. - 0
Reconcile the recent adjuvant trials showing that both more therapy and less therapy are better.	Reconcile the recent adjuvant trials showing that both more therapy and less therapy are better. - 5	Reconcile the recent adjuvant trials showing that both more therapy and less therapy are better. - 4	Reconcile the recent adjuvant trials showing that both more therapy and less therapy are better. - 3	Reconcile the recent adjuvant trials showing that both more therapy and less therapy are better. - 2	Reconcile the recent adjuvant trials showing that both more therapy and less therapy are better. - 1	Reconcile the recent adjuvant trials showing that both more therapy and less therapy are better. - 0
Assess a more personalized approach to patient treatment.	Assess a more personalized approach to patient treatment. - 5	Assess a more personalized approach to patient treatment. - 4	Assess a more personalized approach to patient treatment. - 3	Assess a more personalized approach to patient treatment. - 2	Assess a more personalized approach to patient treatment. - 1	Assess a more personalized approach to patient treatment. - 0
Examine the effectiveness of a cervical pessary on the prevention of prematurity in singletons and twins.	Examine the effectiveness of a cervical pessary on the prevention of prematurity in singletons and twins. - 5	Examine the effectiveness of a cervical pessary on the prevention of prematurity in singletons and twins. - 4	Examine the effectiveness of a cervical pessary on the prevention of prematurity in singletons and twins. - 3	Examine the effectiveness of a cervical pessary on the prevention of prematurity in singletons and twins. - 2	Examine the effectiveness of a cervical pessary on the prevention of prematurity in singletons and twins. - 1	Examine the effectiveness of a cervical pessary on the prevention of prematurity in singletons and twins. - 0
Analyze the relevance and necessity for Pap smears to be performed on a yearly basis.	Analyze the relevance and necessity for Pap smears to be performed on a yearly basis. - 5	Analyze the relevance and necessity for Pap smears to be performed on a yearly basis. - 4	Analyze the relevance and necessity for Pap smears to be performed on a yearly basis. - 3	Analyze the relevance and necessity for Pap smears to be performed on a yearly basis. - 2	Analyze the relevance and necessity for Pap smears to be performed on a yearly basis. - 1	Analyze the relevance and necessity for Pap smears to be performed on a yearly basis. - 0
Discuss new guidelines for annual pelvic exams and evaluate their impact on positive patient outcomes.	Discuss new guidelines for annual pelvic exams and evaluate their impact on positive patient outcomes. - 5	Discuss new guidelines for annual pelvic exams and evaluate their impact on positive patient outcomes. - 4	Discuss new guidelines for annual pelvic exams and evaluate their impact on positive patient outcomes. - 3	Discuss new guidelines for annual pelvic exams and evaluate their impact on positive patient outcomes. - 2	Discuss new guidelines for annual pelvic exams and evaluate their impact on positive patient outcomes. - 1	Discuss new guidelines for annual pelvic exams and evaluate their impact on positive patient outcomes. - 0
Analyze the impact patient and physician breast examinations have on early detection of breast cancer.	Analyze the impact patient and physician breast examinations have on early detection of breast cancer. - 5	Analyze the impact patient and physician breast examinations have on early detection of breast cancer. - 4	Analyze the impact patient and physician breast examinations have on early detection of breast cancer. - 3	Analyze the impact patient and physician breast examinations have on early detection of breast cancer. - 2	Analyze the impact patient and physician breast examinations have on early detection of breast cancer. - 1	Analyze the impact patient and physician breast examinations have on early detection of breast cancer. - 0

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective Speakers are listed according to the lecture schedule.

	5	4	3	2	1
The Breast Cancer Screening Debate: An Opportunity to Move From Debate to Wisdom - Laura Esserman, M.D., MBA	The Breast Cancer Screening Debate: An Opportunity to Move From Debate to Wisdom - Laura Esserman, M.D., MBA - 5	The Breast Cancer Screening Debate: An Opportunity to Move From Debate to Wisdom - Laura Esserman, M.D., MBA - 4	The Breast Cancer Screening Debate: An Opportunity to Move From Debate to Wisdom - Laura Esserman, M.D., MBA - 3	The Breast Cancer Screening Debate: An Opportunity to Move From Debate to Wisdom - Laura Esserman, M.D., MBA - 2	The Breast Cancer Screening Debate: An Opportunity to Move From Debate to Wisdom - Laura Esserman, M.D., MBA - 1
New Concepts in the Management of Severe Preeclampsia - Jack Ludmir, M.D.	New Concepts in the Management of Severe Preeclampsia - Jack Ludmir, M.D. - 5	New Concepts in the Management of Severe Preeclampsia - Jack Ludmir, M.D. - 4	New Concepts in the Management of Severe Preeclampsia - Jack Ludmir, M.D. - 3	New Concepts in the Management of Severe Preeclampsia - Jack Ludmir, M.D. - 2	New Concepts in the Management of Severe Preeclampsia - Jack Ludmir, M.D. - 1
Lessons in Cesarean Section Reduction - David C. Lagrew Jr., M.D.	Lessons in Cesarean Section Reduction - David C. Lagrew Jr., M.D. - 5	Lessons in Cesarean Section Reduction - David C. Lagrew Jr., M.D. - 4	Lessons in Cesarean Section Reduction - David C. Lagrew Jr., M.D. - 3	Lessons in Cesarean Section Reduction - David C. Lagrew Jr., M.D. - 2	Lessons in Cesarean Section Reduction - David C. Lagrew Jr., M.D. - 1
How Can Interventional Radiologist Be Part of the Team? - Constantino S. Peña M.D.	How Can Interventional Radiologist Be Part of the Team? - Constantino S. Peña M.D. - 5	How Can Interventional Radiologist Be Part of the Team? - Constantino S. Peña M.D. - 4	How Can Interventional Radiologist Be Part of the Team? - Constantino S. Peña M.D. - 3	How Can Interventional Radiologist Be Part of the Team? - Constantino S. Peña M.D. - 2	How Can Interventional Radiologist Be Part of the Team? - Constantino S. Peña M.D. - 1
Adaptive Platform Trials: Are We Ready to Move Beyond Large Phase 3 Confirmatory Trials? - Laura Esserman, M.D., MBA	Adaptive Platform Trials: Are We Ready to Move Beyond Large Phase 3 Confirmatory Trials? - Laura Esserman, M.D., MBA - 5	Adaptive Platform Trials: Are We Ready to Move Beyond Large Phase 3 Confirmatory Trials? - Laura Esserman, M.D., MBA - 4	Adaptive Platform Trials: Are We Ready to Move Beyond Large Phase 3 Confirmatory Trials? - Laura Esserman, M.D., MBA - 3	Adaptive Platform Trials: Are We Ready to Move Beyond Large Phase 3 Confirmatory Trials? - Laura Esserman, M.D., MBA - 2	Adaptive Platform Trials: Are We Ready to Move Beyond Large Phase 3 Confirmatory Trials? - Laura Esserman, M.D., MBA - 1
Cervical Pessary for Prevention of Preterm Singleton and Twin Births - Jack Ludmir, M.D.	Cervical Pessary for Prevention of Preterm Singleton and Twin Births - Jack Ludmir, M.D. - 5	Cervical Pessary for Prevention of Preterm Singleton and Twin Births - Jack Ludmir, M.D. - 4	Cervical Pessary for Prevention of Preterm Singleton and Twin Births - Jack Ludmir, M.D. - 3	Cervical Pessary for Prevention of Preterm Singleton and Twin Births - Jack Ludmir, M.D. - 2	Cervical Pessary for Prevention of Preterm Singleton and Twin Births - Jack Ludmir, M.D. - 1
Gynecologic Myths, Mistruths and Current Confusions - Ricardo Estape, M.D.	Gynecologic Myths, Mistruths and Current Confusions - Ricardo Estape, M.D. - 5	Gynecologic Myths, Mistruths and Current Confusions - Ricardo Estape, M.D. - 4	Gynecologic Myths, Mistruths and Current Confusions - Ricardo Estape, M.D. - 3	Gynecologic Myths, Mistruths and Current Confusions - Ricardo Estape, M.D. - 2	Gynecologic Myths, Mistruths and Current Confusions - Ricardo Estape, M.D. - 1

Was this course fair, balanced and without commercial bias? *

Yes

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

If you checked "No,” please tell us why: *

If you checked "No,” please explain why you would not recommend this course: *

Please list specific changes you intend to implement in your daily practice as a result of attending this activity. *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

Leave this field blank

You are here

OBGYN Evaluation - January 26, 2018